Clinical trials: Metastatic Digestive System Carcinoma
Liver Cancer
Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00006010
- Testing
- docetaxel, gemcitabine hydrochloride
- Where
- 17 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate LYL845 in Adults With Solid Tumors
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT05573035
- Testing
- LYL845
- Where
- 18 sites in United States
- Volunteers
- 39 people
- Sponsor
- Lyell Immunopharma, Inc.
Hepatocellular Carcinoma, Liver Neoplasms
A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver
The purpose of this study is to determine the maximum tolerated dose (MTD) of ThermoDox when used in combination with radiofrequency ablation (RFA) in the treatment of primary and metastatic tumors of the liver.
- Trial name
- NCT00441376
- Testing
- ThermoDox
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Imunon
Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
The dual immunotherapy regimen significantly outperformed previous chemotherapy or immunomonotherapy for MSS type advanced CRC in two key efficacy indicators, ORR and PFS.
- Conditions
- Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation, Cadonilimab
- Trial name
- NCT06218810
- Testing
- Cadonilimab + bevacizumab + FOLFOX
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Fudan University
Liver Cancer, Liver Metastasis Colon Cancer
Clinical Validation of a Fractional Administration Device for Holmium-166 SIRT
To investigate the in vivo performance and safety of a novel medical device for the injection of holmium-166 microspheres during radioembolization.
- Conditions
- Liver Cancer, Liver Metastasis Colon Cancer, Primary Liver Cancer
- Trial name
- CONTROL (NCT05183776)
- Testing
- Fractional administration device
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Radboud University Medical Center
Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
This phase II trial studies how well autologous tumor infiltrating lymphocytes MDA-TIL works in treating patients with ovarian cancer, colorectal cancer, or pancreatic ductal adenocarcinoma that has come back (recurrent) or does…
- Conditions
- Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT03610490
- Testing
- Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Hepatocellular, Neoplasm Circulating Cells
Circulating Tumor Cells for Hepatocellular Carcinoma
To explore the clinical value of circulating tumor cells (CTCs) measurement for Hepatocellular carcinoma (HCC) patients.
- Trial name
- CTCs for HCC (NCT01930383)
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
Liver Metastases, Colorectal Cancer
Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer
The trial is a randomized control trial. Patients are randomized between Ltx and other treatment that may include further chemotherapy, TACE, SIRT or other available treatment options.
- Trial name
- SECAIII (NCT03494946)
- Testing
- Liver transplantation, Chemotherapy
- Where
- Norway
- Volunteers
- 30 people
- Sponsor
- Oslo University Hospital
NRG1 Fusion, Pancreatic Cancer
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128…
- Conditions
- NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04100694
- Testing
- MCLA-128
- Sponsor
- Merus B.V.
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Metastatic Pancreatic Carcinoma
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
This study is a single-arm phase II clinical study to include 32 patients with advanced pancreatic cancer with KRAS G12D mutation to evaluate the effectiveness of HRS-4642 combined with nitutuzumab and AG for first-line treatment…
- Trial name
- NCT06770452
- Testing
- HRS-4642, Nimotuzumab, gemcitabine + nab-paclitaxel
- Where
- 2 sites in China
- Volunteers
- 133 people
- Sponsor
- Zhejiang University
Metastatic Colorectal Carcinoma, Multi-organ Metastatic Colorectal Cancer
Local Liver Treatment for Multi-organ Colorectal Cancer Metastases
The purpose of this study was to investigate the effect of only local radical treatment of liver metastases combined with systematic treatment in the treatment of patients with multiple organ metastases of colorectal cancer…
- Conditions
- Metastatic Colorectal Carcinoma, Multi-organ Metastatic Colorectal Cancer, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT06449937
- Testing
- Radical local Surgery, Systemic therapy, Interventional therapy
- Where
- 6 sites in China
- Volunteers
- 130 people
- Sponsor
- Anhui Provincial Hospital
Esophageal Neoplasms, Lymph Node Metastases
Distribution of Lymph Node Metastases in Esophageal Carcinoma
Background: Lymph node status is an important prognostic parameter in esophageal carcinoma and an independent predictor of survival.
- Trial name
- TIGER (NCT03222895)
- Where
- 19 sites in United States, Brazil and 12 more
- Volunteers
- 5,000 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
The purpose of this study is to evaluate the safety and efficacy of S-1 and Cisplatin compared to 5-FU and Cisplatin in treatment of patients with metastatic diffuse gastric and gastro-esophageal junction cancer previously…
- Trial name
- DIGEST (NCT01285557)
- Testing
- S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm), Fluorouracil/cisplatin (control arm)
- Where
- 87 sites in United States, Argentina and 18 more
- Volunteers
- 361 people
- Sponsor
- Taiho Oncology, Inc.
Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma
Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer
Microscopic residual tumor at the resection margin is a critical risk factor for recurrence in patients undergoing hepatectomy for liver cancer, yet current detection relies solely on postoperative pathological examination of the…
- Conditions
- Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07704216
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Unresectable Locally Advanced Pancreatic Carcinoma
A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With Gemcitabine +/- Nab-paclitaxel.
To evaluate the safety of OncoSil™ in a patient population undergoing standard chemotherapy treatment for pancreatic cancer. This study has been designed to satisfy FDA regulatory requirements.
- Trial name
- OncoPaC-1 (NCT03076216)
- Testing
- OncoSil™
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- OncoSil Medical Limited
Metastatic Carcinoma in the Liver, Stage IV Colorectal Cancer
High Definition Single Cell Analysis in Colorectal Cancer
This research clinical trial studies high definition single cell analysis in blood and tissue samples from patients with colorectal cancer which has spread to the liver.
- Trial name
- NCT02809716
- Testing
- Biomarker Analysis, Cytology Specimen Collection Procedure
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Southern California
Colorectal Cancer
Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer
RATIONALE: Brivanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00640471
- Testing
- cetuximab, brivanib alaninate
- Where
- 37 sites in Canada
- Volunteers
- 750 people
- Sponsor
- NCIC Clinical Trials Group
Gastric Cancer, Colon Cancer
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
This study is a open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CART cell preparations, and to reliminarily observe the study drug in CEA-positive advanced…
- Conditions
- Gastric Cancer, Colon Cancer, Rectal Cancer, Breast Cancer
- Trial name
- NCT06126406
- Testing
- CEA-targeted CAR-T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Squamous Cell Carcinoma of the Anus
International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel
Anal cancer is a relatively uncommon disease and there is currently no standard chemotherapy treatment for patients with inoperable locally recurrent or metastatic disease.
- Trial name
- InterAACT (NCT02051868)
- Testing
- Cisplatin, 5-Fluorouracil (5-FU), Carboplatin
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 80 people
- Sponsor
- Royal Marsden NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.